# US 2024/0189244 A1 · Compositions and methods for delivering pharmaceutical agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189244 A1
- Document ID: US20240189244A1
- Status: Published application
- Kind: A1
- Application number: 18/285,971
- Filed: 2022-04-08
- Published: 2024-06-13
- Earliest claimed: 2021-04-09
- Assignees: Arizona Board of Regents on Behalf of the University of Arizona
- Applicants: Arizona Board of Regents on Behalf of the University of Arizona
- Inventors: Heidi Mansour; Rick Schnellmann; David Encinas Basurto; Ernest Vallorz
- Web page: https://patentgrep.com/patent/US20240189244A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions and methods for delivering pharmaceutical agents to the kidney. In particular, provided herein are nanoparticle formulations of β2 adrenergic agonists for use in treating and preventing kidney damage or disease.

## Claims

### Claim 1

A composition, comprising:
a pharmaceutical composition comprising nanoparticles comprising a β2 adrenergic agonist and a polymer.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said β2 adrenergic agonist is interspersed within said polymer.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said β2 adrenergic agonist is selected from the group consisting of albuterol, formoterol, bitolterol, fenoterol, isoproterenol, levalbuterol, metaproterenol, pirbuterol, procaterol, ritodrine, terbutaline, arformoterol, bambuterol, clenbuterol, salmeterol, abediterol, carmoterol, indacaterol, olodaterol, vilanterol, isoxsuprine, mabuterol, and zilpaterol.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said polymer is biocompatible and biodegradable.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said polymer is selected from the group consisting of methyl ether-block-poly(lactide-co-glycolide) (PLGA), poly(vinyl alcohol), chitosan, poly(ε-caprolactone), poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (PLGA-PEG), Poly(lactide-co-glycolide) methyl ether block-poly(ethylene glycol)-amine (PLGA-PEG-HN2), and poly(lactide-co-glycolide) methyl ether block-poly(ethylene glycol)-carboxylic acid (PLGA-PEG-COOH).

### Claim 6 (depends on 5)

The composition of claim 5, wherein said PLGA has an average molecular weight of 10,000 to 100,000 and said PEG has an average molecular weight of 2,000 to 10,000.

### Claim 7 (depends on 6)

The composition of claim 6, wherein said PLGA has an average molecular weight of 55,000 and said PEG has an average molecular weight of 5,000.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said particles are spherical.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said nanoparticles have a diameter of 100 to 800 nm.

### Claim 10 (depends on 1)

The composition of claim 1, wherein said β2 adrenergic agonist is released from said nanoparticle at physiological conditions.

### Claim 11 (depends on 1)

The composition of claim 1, wherein each of said nanoparticles comprises 1 to 5 μg of said β2 adrenergic agonist per mg of nanoparticles.

### Claim 12 (depends on 1)

The composition of claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The composition of claim 1, wherein said nanoparticles are made by a method, comprising:
a) mixing a first solution comprising said β2 adrenergic agonist with a second solution comprising an emulsion of said polymer in a solvent;
b) emulsifying said first solution in said second solution; and
c) removing said solvent.

### Claim 15 (depends on 1)

The composition of claim 1, wherein said nanoparticles are made by a method, comprising:
a) mixing a first solution comprising said β2 adrenergic agonist with a second solution comprising an emulsion of said polymer in a solvent;
b) emulsifying said first solution in said second solution to generate a first emulsion;
c) mixing and emulsifying said first emulsion with a third solution comprising said polymer; and
d) removing said solvent.

### Claim 16 (depends on 1)

A method of treating or preventing kidney disease, comprising:
administering the composition of claim 1 to a subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein said administering is intravenous, intraperitoneal, or subcutaneous administration.

### Claim 18 (depends on 16)

The method of claim 16, wherein said nanoparticles localize to the kidney of said subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein said nanoparticles localize to the tubules of the renal cortex.

### Claim at position 20

20-21. (canceled)

### Claim 22 (depends on 16)

The method of claim 16, wherein said administration results in mitochondrial biogenesis in the renal proximal tubules.

### Claim 23 (depends on 16)

The method of claim 16, wherein said kidney disease is selected from the group consisting of acute renal injury, chronic renal injury, glomerular injury, drug and toxicant induced renal injury, ischemia-reperfusion injury, and diabetic nephropathy

### Claim at position 23

24-26. (canceled)
